Patent application number | Description | Published |
20090221557 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5 RECEPTOR ANTAGONISTS - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 09-03-2009 |
20090221558 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 09-03-2009 |
20110263572 | 3-AMINOALKYL-1,4-DIAZEPAN-2-ONE MELANOCORTIN-5-RECEPTOR ANTAGONISTS - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 10-27-2011 |
Patent application number | Description | Published |
20090131374 | PROTEIN TYROSINE PHOSPHATASE INHIBITORS AND METHODS OF USE THEREOF - The present invention provides compounds of Formula (I) and Formula (II) that are useful for modulating the biological activity of the protein tyrosine phosphatase-1b (PTP1B) enzyme. Compounds of this invention can be used to treat diseases and/or conditions in which the PTP1B enzyme is a factor. Such diseases and/or conditions include, but are not limited to, Type 1 diabetes, Type 2 diabetes, inadequate glucose tolerance, insulin resistance, obesity, hyperlipidemia, hypertriglyceridemia, hypercholesterolemia, low HDL levels, atherosclerosis, vascular restenosis, inflammatory bowel disease, pancreatitis, adipose cell tumors, adipose cell carcinoma, liposarcoma, dyslipidemia, cancer, and neurodegenerative diseases. | 05-21-2009 |
20120141392 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for binding and/or modulating the biological activity of the melanocortin-1 receptor (MC1R). Compounds of this invention can be used to treat diseases and/or conditions in which modulation of MC1R is beneficial. Such diseases and/or conditions include, but are not limited to, hyperpigmentation (including melasma), hypopigmentation (including vitiligo), melanoma, basal cell carcinoma, squamous cell carcinoma, erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, photosensitivity, sunburn, inflammatory diseases, aberrant fibroblast activity and pain. | 06-07-2012 |
20130225563 | METHODS OF MODULATING THE ACTIVITY OF THE MC5 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for modulating the biological activity of the melanocortin-5 receptor (MC5R). Compounds of this invention can be used to treat diseases and/or conditions in which downregulation of MC5R is beneficial. Such diseases and/or conditions include, but are not limited to, acne, seborrhea, seborrheic dermatitis, cancer, and inflammatory diseases. | 08-29-2013 |
20140128380 | METHODS OF MODULATING THE ACTIVITY OF THE MC1 RECEPTOR AND TREATMENT OF CONDITIONS RELATED TO THIS RECEPTOR - The present invention provides compounds of Formula (I) that are useful for binding and/or modulating the biological activity of the melanocortin-1 receptor (MC1R). Compounds of this invention can be used to treat diseases and/or conditions in which modulation of MC1R is beneficial. Such diseases and/or conditions include, but are not limited to, hyperpigmentation (including melasma), hypopigmentation (including vitiligo), melanoma, basal cell carcinoma, squamous cell carcinoma, erythropoietic protoporphyria, polymorphous light eruption, solar urticaria, photosensitivity, sunburn, inflammatory diseases, aberrant fibroblast activity and pain. | 05-08-2014 |
Patent application number | Description | Published |
20110091549 | Modulating Drug Release Rate By Controlling The Kinetics Of The pH Transition In Hydrogels - Methods and compositions relate to modulating the release profile of drug molecules from a hydrogel by controlling the kinetics of the pH transition of the hydrogel. The hydrogel is formed by in situ polymerization and includes a drug molecule having a pKa between the pH of the formed hydrogel and the physiologic environment in which the hydrogel is placed. | 04-21-2011 |
20110092899 | Prevention Of Premature Gelling Of Delivery Devices For pH Dependent Forming Materials - The present disclosure provides treatment of an apparatus, in embodiments a delivery device, which prevents premature gelling of any materials or precursor(s) of a pH dependent forming material, in embodiments a hydrogel, dispensed by the delivery device. The pH microenvironment near the surface of a lumen of the device, in embodiments the tip of a spray applicator through which the material to be dispensed is expelled from the device, may be controlled to prevent premature gelling. | 04-21-2011 |
20110093057 | Mitigating Thrombus Formation On Medical Devices By Influencing pH Microenvironment Near The Surface - The present disclosure provides treatments of medical devices which inhibit thrombus formation. At least a portion of a substrate of a medical device includes a surface possessing a functionality and/or surface charge adapted to modulate the pH of the surface of the medical device, as well as the pH microenvironment near the surface of a medical device. | 04-21-2011 |
20120156289 | Biodegradable Osmotic Pump Implant For Drug Delivery - The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing. | 06-21-2012 |
20120175810 | Drug Delivery Implants, Systems And Methods For Making - The present disclosure provides implants suitable for drug delivery. In embodiments, the present disclosure provides layered biodegradable drug delivery implants and systems and methods for making these implants. | 07-12-2012 |
20120197028 | Crosslinked Polymers with the Crosslinker as Therapeutic For Sustained Release - Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form. | 08-02-2012 |
20130156935 | Methods for Coating Medical Devices - Processes for coating medical devices are provided herein. The processes include heating a surface of the particles used to form the coating as the particles are being applied to the medical device. The resulting coating has improved adherence to the medical device, and does not require the use of solvents and/or water, obviating the need for any steps that otherwise might be required to remove these solvents and/or water. Sufficient adherence of the particles to the medical device may also occur without the need for heating the substrate used to form the medical device. | 06-20-2013 |
20130225857 | Crosslinked Polymers with the Crosslinker as Therapeutic for Sustained Release - Crosslinked polymers, methods for their preparation and use, are described in which the crosslinked polymers are formed from at least two polymer precursors, one of which is designed, upon degradation of the crosslinked polymer, to release the second polymer precursor in its original, unmodified chemical form. | 08-29-2013 |
20140005375 | Medical Devices Based On Oxidized Cellulose | 01-02-2014 |
20140005376 | Dissolution of Oxidized Cellulose and Particle Preparation by Solvent and Non-Solvent Precipitation | 01-02-2014 |
20140005377 | Dissolution of Oxidized Cellulose and Particle Preparation by Dispersion and Neutralization | 01-02-2014 |
20140005378 | Dissolution of Oxidized Cellulose and Particle Preparation by Cross-Linking With Multivalent Cations | 01-02-2014 |
20140274944 | Sprayable Hemostat Using Soluble Oxidized Cellulose With Miniaturized Electrospray System And Method - An applicator for forming a film is disclosed. The applicator includes: a first extension tube coupled to a source of a modified cellulose solution; a shaft coupled to the first extension tube at a proximal end thereof, the shaft defining a first lumen in fluid communication with the first extension tube for transmission of the modified cellulose solution through the shaft; and an atomizer disposed at a distal end of the and configured to atomize the modified cellulose solution into a plurality of particles. | 09-18-2014 |
20140274945 | Resorbable Oxidized Cellulose Embolization Microspheres - A method for forming an embolism within a blood vessel is disclosed. The method includes including: implanting a plurality of oxidized cellulose microspheres into a lumen of a blood vessel to at least partially block the lumen. | 09-18-2014 |
Patent application number | Description | Published |
20130296833 | BIODEGRADABLE OSMOTIC PUMP IMPLANT FOR DRUG DELIVERY - The present disclosure relates to a drug delivery device including a biodegradable housing and a hydrogel within the biodegradable housing. The housing, the hydrogel, or both, may include a bioactive agent. Also disclosed is a method of drug delivery including the steps of forming the biodegradable housing, in embodiments a hydrogel, suspending a bioactive agent in the hydrogel, and introducing a second hydrogel and/or precursors of a second hydrogel into the biodegradable housing. | 11-07-2013 |
20130324910 | ABLATION DEVICE WITH DRUG DELIVERY COMPONENT AND BIOPSY TISSUE-SAMPLING COMPONENT - An ablation device includes a handle assembly, an ablation electrode extending from the handle assembly, and one or more delivery needles extending from the handle assembly. The ablation electrode includes an ablation needle. The ablation needle includes a distal end portion including a drug delivery port defined therethrough. The ablation device also includes and a biopsy tool extending from the handle assembly. | 12-05-2013 |
20130324911 | ABLATION DEVICE WITH DRUG DELIVERY COMPONENT - An ablation system includes a source of electrosurgical energy, a source of coolant fluid, and an ablation electrode assembly operatively connected to the source of electrosurgical energy and fluidly-coupled to the source of coolant fluid. The ablation electrode assembly includes a hub defining a chamber therein and one or more electrically-conductive ablation needles extending from the hub. The ablation system also includes one or more delivery needles extending from the hub. The one or more delivery needles are selectively moveable from a first position, wherein the distal end of the delivery needle is disposed proximal to the distal end portion of the ablation needle, to at least a second position, wherein at least the distal end of the delivery needle is disposed distally beyond the distal end portion of the ablation needle. | 12-05-2013 |
20140079790 | MULTI-ENCAPSULATED FORMULATIONS MADE WITH OXIDIZED CELLULOSE FOR IN-SITU REACTIONS - A microsphere and methods for forming the same are disclosed. The microsphere includes modified cellulose and at least one of precursors for is-situ polymerization or endothermic/exothermic reactions. | 03-20-2014 |
20150065944 | DRUG-DELIVERY DEVICE FOR USE WITH ABLATION DEVICE - A drug-delivery device includes a body configured for attachment to a handle of an ablation device, a shaft portion defining a passageway therein, and a delivery lumen to provide for drug delivery to tissue. The body includes a proximal portion, a distal portion, and a contoured portion disposed therebetween. The contoured portion is configured for engagement with a contoured portion of the handle of the ablation device. The shaft portion includes a proximal end and a distal end. The proximal end of the shaft engages with an opening defined in the distal end of the body. The passageway of the shaft portion is configured to receive the delivery lumen slideably moveably therein. The delivery lumen includes a proximal portion and a distal portion. The drug-delivery device also includes a knob member coupled to the proximal portion of the delivery lumen. | 03-05-2015 |
20150065964 | DRUG-DELIVERY CANNULA ASSEMBLY - A drug-delivery cannula assembly includes a cannula housing adapted for receiving at least one obturator shaft of an obturator assembly therethrough, one or more cannulae, and a supply line coupled to the cannula housing. The cannula housing is adapted for receiving one or more obturator shafts of an obturator assembly therethrough. The one or more cannulae define a longitudinal axis and a passageway aligned with the longitudinal axis. The one or more cannulae each include a proximal end coupled to the cannula housing. The cannula housing is configured to fluidly-couple the one or more cannulae to a source of a drug delivery supply for supplying drugs via the supply line to the one or more cannulae. | 03-05-2015 |